Investigational drug · Phase 3
Sitravatinib
Also called: MGCD516
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Malignancies, Advanced or Metastatic Solid Malignancies.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
35
Any phase or sponsor naming "Sitravatinib"
First trial start
2019
Dec 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sitravatinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignancies
- Advanced or Metastatic Solid Malignancies
Largest trials
Live from ClinicalTrials.gov: studies naming "Sitravatinib" as an intervention, largest first.
- Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerPivotal-lookingTerminated
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT03906071 · 577 participants · Start Jul 15, 2019 · Primary completion Mar 20, 2023
Drug: Nivolumab; Sitravatinib and 1 more · For: Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sites: Birmingham, Alabama; Huntsville, Alabama; Glendale, Arizona · 261 sites in all
University of BirminghamAcademic, hospital or other
NCT02664935 · 423 participants · Start May 13, 2015 · Primary completion Nov 29, 2023
Drug: AZD4547; Vistusertib and 9 more · For: Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma
Sites: Aberdeen, United Kingdom; Belfast, United Kingdom; Birmingham, United Kingdom · 25 sites in all
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesPivotal-lookingCompleted
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04164199 · 404 participants · Start Dec 19, 2019 · Primary completion May 23, 2026
Drug: Tislelizumab; Pamiparib and 11 more · For: Advanced Malignancies
Sites: Miami, Florida; New York, New York; Nashville, Tennessee · 106 sites in all
- Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingTerminated
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT04921358 · 377 participants · Start Jul 27, 2021 · Primary completion Dec 20, 2023
Drug: Tislelizumab; Docetaxel and 1 more · For: Non-Small Cell Lung Cancer (NSCLC)
Sites: Blacktown, Australia; Campbelltown, Australia; Cudgen, Australia · 61 sites in all
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT03606174 · 260 participants · Start Sep 11, 2018 · Primary completion Aug 3, 2022
Drug: Sitravatinib; Nivolumab and 2 more · For: Urothelial Carcinoma; Urothelial Carcinoma Bladder; Urothelial Carcinoma Ureter and 2 more
Sites: Tucson, Arizona; Irvine, California; Aurora, Colorado · 36 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03666143 · 216 participants · Start Nov 1, 2018 · Primary completion Jan 5, 2023
Drug: Sitravatinib; Tislelizumab · For: Advanced Solid Tumors
Sites: Blacktown, Australia; South Brisbane, Australia; Clayton, Australia · 19 sites in all
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT02219711 · 193 participants · Start Aug 2014 · Primary completion Apr 27, 2022
Drug: MGCD516 · For: Advanced Cancer
Sites: Birmingham, Alabama; San Diego, California; San Francisco, California · 43 sites in all
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT02954991 · 161 participants · Start Nov 7, 2016 · Primary completion Nov 4, 2021
Drug: Glesatinib; Sitravatinib and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Yuma, Arizona; Beverly Hills, California; Duarte, California · 25 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03941873 · 111 participants · Start Feb 28, 2019 · Primary completion Mar 31, 2023
Drug: Sitravatinib; Tislelizumab · For: Carcinoma, Hepatocellular; Gastric/Gastroesophageal Junction Cancer
Sites: Hefei, China; Beijing, China; Fuzhou, China · 18 sites in all
Fudan UniversityAcademic, hospital or other
NCT04734262 · 98 participants · Start Apr 1, 2021 · Primary completion Jun 1, 2026
Drug: Sitravatinib; Tislelizumab and 1 more · For: Metastatic Breast Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Corrigendum to "Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations" [Translational Oncology 58 (2025) 102467].
Yang J, Zhang Y, Li Q, et al. · Transl Oncol 2026
- Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer.
Yoon J, Lee CK, Kim JW, et al. · J Hepatol 2026
- Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive-stage small-cell lung cancer: Results of two prospective phase II studies.
Yu S, Li H, Lu H, et al. · Int J Cancer 2026
- Metabolic Profiling of Sitravatinib in Rat and Human Liver Microsomes Using LC-MS/MS and LC-Orbitrap-HRMS.
Xu S, Zhu Y, Liu W, et al. · Rapid Commun Mass Spectrom 2026
- SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhou Q, Gao B, Hu J, et al. · BMJ Oncol 2026
- Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).
Liu XY, Sui XY, Xu Y, et al. · Mol Cancer 2025
Also in development for Advanced Malignancies
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
- TQB3616Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- BGB-15025Phase 33 trials
BeOne Medicines (BeiGene) · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Advanced Malignancies
- SurzebiclimabBGB-A425Phase 33 trials
BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- CMP 001VidutolimodPhase 32 trials
Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.